Harmony Biosciences appoints Linda Szyper to Board of Directors

Harmony Biosciences Holdings, Inc.

Linda Szyper, former COO of McCann Health, appointed as Class II director effective Nov 18, 2021.
She fills vacancy created by resignation of Eric L. Motley in August 2021.
Will serve on the Nominating and Corporate Governance Committee; deemed independent under Nasdaq.
Over 30 years experience in pharma marketing, commercialization, and healthcare communications.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Linda Szyper

Class II director

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2021-11-18
Filed: November 22, 2021, 6:59 PM ET

Effective November 18, 2021, the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) appointed Linda Szyper, age 56, as a Class II director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Linda Szyper was appointed as Class II director at Harmony Biosciences Holdings, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

Effective November 18, 2021, the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) appointed Linda Szyper, age 56, as a Class II director

View on SEC.gov

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-21-016275

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.